Search for dissertations about: "disseminated tumour cells"
Showing result 11 - 15 of 16 swedish dissertations containing the words disseminated tumour cells.
-
11. Astatine-211 and Iodine Conjugates: Radiohalogenation and Preclinical Pharmacokinetics for Targeted and Pretargeted Radioimmunotherapy
Abstract : Endoradiotherapy using labelled tumour specific-monoclonal antibodies in the therapy of malignant disease is a therapeutic modality that is coming of age. While clearly defined tumours can be treated with surgery and/or chemotherapy, occult metastases requires adjuvant systemic treatment, e.g. READ MORE
-
12. Prognostic Factors in Breast Cancer
Abstract : Breast cancer is increasing in the industrialised countries. Due to early detection and adjuvaut treatment with radiotherapy, hormones and chemotherapy, mortality has decreased. The different adjuvant treatments have adverse effects. READ MORE
-
13. DNA ploidy, proliferation markers and prognosis in malignant melanoma
Abstract : Malignant melanoma is a serious disease when metastases occur. It is therefore important to investigate possible tools for prediction to the outcome of the disease. In the present investigation 265 patients with cutaneous malignant melanoma and uveal melanoma was investigated with flow cytometry. READ MORE
-
14. Colorectal Cancer - Evaluation of MMP as a prognostic marker and a model for peritoneal response
Abstract : Background : There are about 6600 patients diagnosed with colorectal cancer in Sweden each year. Survival rates vary with cancer stage at diagnosis. The main treatment is surgery together with, in some cases, oncological treatment. Matrix metalloproteinases (MMP) are deeply involved in the growth and spread of colorectal cancer tumours. READ MORE
-
15. Individually Tailored Toxicity-based Chemotherapy : Studies on Patients with Primary and Metastatic Breast Cancer
Abstract : Standard dosing of chemotherapy based on body surface area (BSA) results in large individual differences in toxicity due to a large inter-patient variability in pharmacokinetics (PK) and pharmacodynamics (PD). This results in under-dosing in certain patients with a potentially weaker antitumoral effect. READ MORE